Specimen Collection Cards Market to Reach US$ 671.2 Mn by 2032, Says Persistence Market Research

The global specimen collection cards market is charting a steady growth trajectory, driven by increasing demand for innovative sample collection and storage tools in health diagnostics, genomics, pharmacokinetics and forensic science. These cards - used for collecting, storing and transporting biological specimens (especially dried blood spot [DBS] cards) - are gaining wider adoption owing to their ease of use, ambient‐temperature stability and capability to simplify logistics in remote or decentralized settings. According to one forecast, the market will grow from an estimated ~US$ 477.0 million in 2025 to about US$ 671.2 million by 2032, at a compound annual growth rate (CAGR) of around 5.0 %.

In terms of market statistics, the blood‐sample segment is expected to account for approximately 88.4% of specimen collection card usage in 2025, highlighting the dominance of dried blood spot applications. On the product front, the well‐established brand card "Whatman 903" is projected to hold nearly 41.7% share in 2025, owing to its strong performance in analyte recovery and regulatory acceptance. Geographically, North America leads the market - estimated at around 35.4% share in 2025 - thanks to high adoption of home sampling, government funding for infectious disease surveillance and established newborn screening infrastructure.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/35329

Driving much of the growth are key factors such as rising demand for remote, decentralized testing; the surge in genetic, RNA/DNA sample preparation; greater emphasis on newborn screening and infant diagnostics; and growth in forensic, epidemiological, and large-scale screening programmes. These drivers position the specimen collection cards market for sustained expansion. Among the segments, the blood-based specimen category leads because it continues to be the most validated and widely adopted specimen type for DBS workflows. Regionally, North America leads, not only because of its established screening and diagnostics ecosystem but also due to favourable reimbursement, regulatory pathways and strong private-and public sector investment.

Key Highlights from the Report

• The global specimen collection cards market is projected to reach approximately US$ 671.2 million by 2032 from around US$ 477.0 million in 2025, at a CAGR of ~5.0%.
• The blood-sample specimen type will dominate with roughly 88.4% share in 2025, thanks to broad use in hormone, metabolite and drug testing.
• "Whatman 903" product segment is expected to hold about 41.7% of the market in 2025, driven by its high analyte-recovery and regulatory acceptance.
• North America is poised to generate about 35.4% of the global market in 2025, supported by high adoption of at-home sampling, newborn screening and infectious disease surveillance.
• The rise of telehealth, direct-to-consumer (DTC) genetic testing and mail-in diagnostics is driving demand for user-friendly, ambient-storage specimen collection cards.
• Forensic toxicology and remote field-based collection are emerging as significant opportunities for specimen collection cards, especially in non-clinical, decentralized contexts.

Market Segmentation

The specimen collection cards market can be segmented in multiple ways to understand its underlying structure and growth dynamics. Firstly, by specimen type, the market includes blood, saliva, urine, buccal cells and other biological specimen formats. The blood specimen segment dominates the market because DBS cards are widely accepted for hormone analysis, therapeutic drug monitoring and newborn screening. While saliva, urine and buccal‐cell based cards show slower penetration today, they are growing as non-invasive alternatives and for self-collection in DTC testing scenarios.

Secondly, by product type, the market is divided into established filter-paper formats such as Whatman 903, treated cards like FTA (for nucleic acid stabilization), and other brands/materials such as Ahlstrom 226. Whatman 903 remains the leading product, while FTA cards are growing rapidly due to DNA/RNA sample preservation capabilities. Next, by application, segmentation covers newborn screening, infectious disease testing, molecular/genomic research, forensic/ toxicology analysis, and home/tele-health testing. Newborn screening remains a major application, while research and forensic uses are growing more quickly. Finally, by end-user, the market includes hospitals & clinics, diagnostic centres/laboratories, home/consumer testing services, and government/public health programmes. Hospitals & clinics currently capture the largest share, but home/tele-health collection services are gaining traction, driven by convenience and remote-sampling trends.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/specimen-collection-cards-market.asp

Regional Insights

Regionally, the market shows distinct trends across major geographies. In North America, the U.S. leads adoption with widespread newborn screening (more than 4 million newborns tested annually), strong infrastructure for remote sampling, and high forensic/ law-enforcement uptake of collection cards in buccal or blood spot formats. This positions the region to maintain a dominant share through the forecast period.

In Asia Pacific, growth is accelerating, particularly in countries such as India and China, due to expanding public health programmes, large underserved rural populations, decentralised diagnostics and ambitious disease-screening initiatives. For example, India's national child health mission aims to screen hundreds of millions of children, boosting DBS card usage. In Middle East & Africa, adoption is increasingly driven by newborn screening roll-outs and infectious disease surveillance in remote settings, where specimen collection cards help circumvent cold-chain logistics.

Although overall share is lower, growth prospects are significant. In Latin America & Europe, mature diagnostics markets support steady uptake, while structural and regulatory barriers constrain rapid expansion. Overall, the regional picture highlights North America as the current frontrunner, with Asia Pacific representing the fastest‐growing regional opportunity.

Market Drivers

One of the most important drivers of the specimen collection cards market is the rising demand for genetic testing, multi-omics research, remote sampling and decentralized diagnostics. Cards that stabilize DNA and RNA at ambient temperatures have enabled sample collections outside of conventional laboratory settings, opening opportunities for large‐scale field studies, population screening, newborn screening, at-home health kits and biobanking initiatives. The trend toward telehealth and mail-in diagnostics further fuels the shift: more consumers are self-collecting saliva or blood drops at home and mailing them to labs, which in turn increases demand for simple, stable sample collection formats. As laboratories and public-health programmes seek to bypass costly cold-chain logistics and improve accessibility in rural or resource-limited regions, specimen collection cards meet these needs and thus act as a prime growth enabler.

Market Restraints

However, the market is not without its limitations. A primary restraint is the so-called hematocrit bias inherent in many dried blood spot (DBS) methods: variations in blood viscosity or cell/plasma ratio significantly impact how blood spreads and dries on the card, which in turn can produce inconsistent analyte concentrations and compromise quantitative reliability. Studies have indicated that hematocrit levels from 20% to 65% may cause up to ~35% variation in analyte measurement, undermining accuracy in critical diagnostic applications such as therapeutic drug monitoring or pediatric hormone screening. Such variability poses a barrier to adoption of DBS cards in highly regulated diagnostic settings where reproducibility and precision are vital. Furthermore, issues of sample integrity, standardization of collection and processing, regulatory acceptance and reimbursement in certain geographies further limit broader uptake of specimen collection cards.

Market Opportunities

The market presents compelling opportunities, particularly in the forensic/toxicology and home-sampling domains. As law enforcement and forensic labs seek efficient, tamper-evident, ambient-temperature stable sample collection formats, dried matrix spot cards (for saliva, urine, blood) are increasingly relied upon. With synthetic opioids and designer drugs driving a surge in demand for remote toxicology screening, specimen collection cards are well-positioned to meet this need. Moreover, the growth of direct-to‐consumer genetic testing, wellness screening, biobanking and decentralized clinical trials opens additional channels for specimen collection cards. As sample collection moves outside traditional clinics into homes, remote sites and field settings, products that simplify logistics without cold chain appeal broadly-presenting the manufacturers with a wide canvas of growth.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/35329

Company Insights
Key players operating in the specimen collection cards market include:

• QIAGEN N.V.
• PerkinElmer Inc.
• Danaher Corporation
• DBS System SA
• GenTegra LLC
• CENTOGENE N.V.
• Eastern Business Forms, Inc.
• Ahlstrom Munksjö
• ARCHIMED Life Science GmbH
• FortiusBio

Market Segmentation

By Specimen Type

Blood
Saliva
Urine
Buccal Cells
Others

By Material

Cotton and Cellulose-based
Fiber-based
Others

By Product

Whatman 903
Ahlstrom 226
FTA
Others

By Application

Newborn Screening
Infectious Diseases Testing
Therapeutic Drug Monitoring
Forensics
Research
Wellbeing/Health Monitoring
Others

By Region

North America
Europe
East Asia
South Asia and Oceania
Latin America
Middle East and Africa
Recent Developments:

In November 2024, Capitainer (Sweden) introduced the "CapitainerSEP10" card designed for finger-prick blood sampling that generates a plasma-like sample without centrifugation, enhancing at-home sampling feasibility.

In February 2024, a collaboration of researchers at Baylor College of Medicine, Medical University of South Carolina and Capitainer announced adoption of dried blood spot (DBS) technology to develop dried fecal spot (DFS) cards, enabling ambient storage of fecal samples on card formats.

Conclusion

In summary, the specimen collection cards market is undergoing a robust evolution, driven by the growing need for simplified sample collection, ambient storage, remote/field diagnostics and decentralized health testing. The dominance of blood‐based specimen types, the continued strength of trusted products such as Whatman 903, and the leadership of North America all paint a picture of a maturing yet dynamic market. While challenges such as hematocrit bias, regulatory hurdles and standardization issues remain, the expanding frontiers of tele-health, forensic toxicology, personalized medicine and global screening programmes present new avenues for growth. For manufacturers, stakeholders and investors, the ability to innovate in materials, formats, ease of use and integration with molecular diagnostics will be critical to capturing the opportunity ahead.

Buy Now the Detailed Report:

Contract Research Organization (CRO) Services Market https://www.persistencemarketresearch.com/market-research/contract-research-organization-cro-services-market.asp
Therapeutic Albumin Market https://www.persistencemarketresearch.com/market-research/therapeutic-albumin-market.asp
Bovine Vaccines Market https://www.persistencemarketresearch.com/market-research/bovine-vaccines-market.asp
Prostate Cancer Hormone Therapy Market https://www.persistencemarketresearch.com/market-research/prostate-cancer-hormone-therapy-market.asp

Contact Us:

Persistence Market Research
Second Floor, 150 Fleet Street, London, EC4A 2DQ, United Kingdom
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.